https://www.selleckchem.com/mTOR.html
In patients with advanced non-small-cell lung cancer (aNSCLC), tumor mutational burden (TM may vary by genomic ancestry; however, its impact on treatment outcomes is unclear. This retrospective, observational study describes treatment patterns of patients with aNSCLC by genomic ancestry and electronic health record (EHR)-reported race and/or ethnicity and evaluates differences in TMB, cancer immunotherapy (CIT) access, and treatment outcomes across racial and ancestral groups. Patients diagnosed with aNSCLC after January 1, 2011, were selected fr
Gefällt mir
Kommentar
Teilen
